IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
IN8bio, Inc. (Nasdaq: INAB) announced a significant milestone with an oral presentation for its Phase 1 study of INB-200 at the 2023 ASCO Annual Meeting on June 2, 2023. This study evaluates the safety and efficacy of INB-200, a treatment targeting glioblastoma multiforme (GBM), a challenging brain cancer. Current treatments provide limited median progression-free survival of 6-7 months and overall survival of 14-16 months. INB-200 utilizes genetically engineered gamma-delta T cells aimed at enhancing cancer cell elimination and potentially prolonging patient survival. The abstract will be publicly accessible on ASCO's website from May 25, 2023. IN8bio also advances its DeltEx platform for developing innovative cancer therapies, currently conducting two Phase 1 trials and planning a Phase 2 trial for newly diagnosed GBM.
- Oral presentation at 2023 ASCO could enhance visibility and credibility for INB-200.
- Phase 1 study results may indicate potential for improving survival rates in GBM patients.
- GBM has a historically low median progression-free survival and overall survival, highlighting treatment challenges.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from June 2-6, 2023. The oral presentation will highlight new Phase 1 study results evaluating the safety, tolerability and efficacy of INB-200, a potentially promising treatment for newly diagnosed glioblastoma multiforme (GBM).
“We are excited that the Phase I trial of INB-200 in GBM has been selected for an oral presentation at ASCO,” said William Ho, CEO and co-founder of IN8bio. “GBM is a highly aggressive and difficult-to-treat brain cancer, where treatment options have remained largely unchanged for almost two decades. The current median progression-free survival with the standard of care for GBM is 6-7 months and overall survival is only 14-16 months. We believe that our unique approach to solid tumor cancers targeting the DNA damage response with our genetically engineered gamma-delta T cells may eliminate more cancer cells and potentially prolong the time to relapse or death.”
Details of the oral presentation are as follows:
Abstract Title: INB-200 Phase I Study of Gene Modified Autologous Gamma-Delta (γδ) T Cells in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) Receiving Maintenance Temozolomide (TMZ)
Abstract #: 2007
Session: S100a - Central Nervous System Tumors
Date and Time: Friday, June 2, 2023, 2:45 PM CDT (3:45 PM EDT)
The abstract will be available on Thursday, May 25 at 5:00 PM EDT on ASCO.org.
About INB-200
INB-200 is a genetically modified autologous drug resistant immunotherapy (DRI) product candidate for the treatment of solid tumors. This novel platform utilizes genetic engineering to generate chemotherapy resistant gamma delta T cells which can be administered concurrently with standard-of-care treatment in solid tumors. This is a powerful, synergistic treatment approach enabling gamma-delta T cells to persist in the presence of chemotherapy, and maintain their natural ability to recognize, engage and kill cancer cells.
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors and our initial indication is in GBM.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively and specifically identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with hematologic malignancies undergoing haploidentical hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored multi-center Phase 2 clinical trial in newly diagnosed glioblastoma, which received IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the ability of INB-200 to eliminate cancer cells and prolong the time to relapse or death; and the timing of initiation, progress and scope of clinical trials for IN8bio’s product candidates. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; expectations for regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 30, 2023, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com
Investors & Media Contact:
Argot Partners
IN8bio@argotpartners.com
FAQ
What is the purpose of IN8bio's Phase 1 study of INB-200?
When will the results of the INB-200 study be presented?
What are the survival rates for GBM with current treatments?
How does INB-200 aim to improve treatment outcomes for GBM?
What is the significance of the presentation at ASCO for IN8bio?
